Literature DB >> 21178626

Trends in chronic obstructive pulmonary disease in the Asia-Pacific regions.

Wan C Tan1.   

Abstract

PURPOSE OF REVIEW: The burden of chronic obstructive pulmonary disease (COPD) is rapidly growing in the Asia-Pacific region. There is the need for region-specific research and analysis of the epidemiology of COPD to raise awareness of the disease and highlight its causes. Such information is essential to for the development of effective national health policies to ensure evidence-based deployment of finite healthcare resources in the prevention and management of COPD. RECENT
FINDINGS: Recent population-based epidemiological studies have confirmed previous assumptions that COPD in the Asia-Pacific region is as prevalent as in the mature economies of the western world. The greatest numbers of deaths and hospitalizations from COPD are concentrated in this populous region of the world. The patterns in trends in mortality and hospitalization in the past 10 years in Asia-Pacific countries show a spectrum from the 'mature' to the 'evolving' and are likely related to the combined effects of cigarette smoking and nonsmoking risk factors. Gross underdiagnosis of COPD and underutilization of spirometry further contribute to burden and are barriers to appropriate and timely management of COPD.
SUMMARY: COPD is a common disease with a large disease burden throughout the Asia-Pacific region. Effective public health preventive measures coupled with timely case detection are needed for the reversal of trends and the reduction of disease burden.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21178626     DOI: 10.1097/MCP.0b013e32834316cd

Source DB:  PubMed          Journal:  Curr Opin Pulm Med        ISSN: 1070-5287            Impact factor:   3.155


  7 in total

1.  Is there a regulatory role of immunoglobulins on tissue forming cells relevant in chronic inflammatory lung diseases?

Authors:  Michael Roth
Journal:  J Allergy (Cairo)       Date:  2011-11-02

2.  Validation of the GOLD 2017 and new 16 subgroups (1A-4D) classifications in predicting exacerbation and mortality in COPD patients.

Authors:  Meng-Zhi Han; Tzuen-Ren Hsiue; Sheng-Han Tsai; Tang-Hsiu Huang; Xin-Min Liao; Chiung-Zuei Chen
Journal:  Int J Chron Obstruct Pulmon Dis       Date:  2018-10-18

3.  Comparison of clinical baseline characteristics between Asian and Western COPD patients in a prospective, international, multicenter study.

Authors:  Kyu Yean Kim; Marc Miravitlles; Pawel Sliwinski; Richard Costello; Victoria Carter; Jessica Tan; Therese Sophie Lapperre; Bernardino Alcazar; Caroline Gouder; Cristina Esquinas; Juan Luis García-Rivero; Anu Kemppinen; Augustine Tee; Miguel Roman-Rodríguez; Juan José Soler-Cataluña; David Price; Chin Kook Rhee
Journal:  Int J Chron Obstruct Pulmon Dis       Date:  2019-07-25

4.  Development and validation of a prediction index for recent mortality in advanced COPD patients.

Authors:  Tzuen-Ren Hsiue; Chiung-Zuei Chen; Sheng-Han Tsai; Chia-Yin Shih; Chin-Wei Kuo; Xin-Min Liao; Peng-Chan Lin; Chian-Wei Chen
Journal:  NPJ Prim Care Respir Med       Date:  2022-01-13       Impact factor: 2.871

5.  Knowledge of communicable and noncommunicable diseases among Karen ethnic high school students in rural Thasongyang, the far northwest of Thailand.

Authors:  Thaworn Lorga; Myo Nyein Aung; Prissana Naunboonruang; Piyatida Junlapeeya; Apiradee Payaprom
Journal:  Int J Gen Med       Date:  2013-07-01

6.  Prognostic utility of the 2011 GOLD classification and other multidimensional tools in Asian COPD patients: a prospective cohort study.

Authors:  Hiang Ping Chan; Amartya Mukhopadhyay; Pauline Lee Poh Chong; Sally Chin; Xue Yun Wong; Venetia Ong; Yiong Huak Chan; Tow Keang Lim; Jason Phua
Journal:  Int J Chron Obstruct Pulmon Dis       Date:  2016-04-22

7.  Global, regional, and national prevalence of, and risk factors for, chronic obstructive pulmonary disease (COPD) in 2019: a systematic review and modelling analysis.

Authors:  Davies Adeloye; Peige Song; Yajie Zhu; Harry Campbell; Aziz Sheikh; Igor Rudan
Journal:  Lancet Respir Med       Date:  2022-03-10       Impact factor: 102.642

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.